After finishing at $5.19 in the prior trading day, Revance Therapeutics Inc (NASDAQ: RVNC) closed at $4.87, down -6.17%. In other words, the price has decreased by -$0.3200 from its previous closing price. On the day, 967811 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of RVNC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 3.80.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $16 previously.
On January 09, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $30 to $8.
Exane BNP Paribas Upgraded its Underperform to Neutral on August 16, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 18 ’24 when Schilke Tobin sold 9,361 shares for $5.04 per share. The transaction valued at 47,204 led to the insider holds 192,666 shares of the business.
Sjuts Dustin S sold 9,211 shares of RVNC for $46,446 on Mar 18 ’24. The President now owns 167,550 shares after completing the transaction at $5.04 per share. On Mar 18 ’24, another insider, Moxie Dwight, who serves as the CLO & GC of the company, sold 8,125 shares for $5.04 each. As a result, the insider received 40,971 and left with 137,815 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RVNC now has a Market Capitalization of 507.53M and an Enterprise Value of 732.05M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.17. Its current Enterprise Value per Revenue stands at 3.13 whereas that against EBITDA is -2.52.
Stock Price History:
Over the past 52 weeks, RVNC has reached a high of $37.98, while it has fallen to a 52-week low of $4.77. The 50-Day Moving Average of the stock is 5.7183, while the 200-Day Moving Average is calculated to be 12.7226.
Shares Statistics:
The stock has traded on average 1.80M shares per day over the past 3-months and 1.79M shares per day over the last 10 days, according to various share statistics. A total of 104.21M shares are outstanding, with a floating share count of 93.53M. Insiders hold about 10.42% of the company’s shares, while institutions hold 75.38% stake in the company. Shares short for RVNC as of Feb 29, 2024 were 11.88M with a Short Ratio of 6.59, compared to 12.65M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.47% and a Short% of Float of 15.35%.
Earnings Estimates
Its stock is currently analyzed by 4 different market analysts. On average, analysts expect EPS of -$0.75 for the current quarter, with a high estimate of -$0.5 and a low estimate of -$1.19, while EPS last year was -$0.74. The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.46 and low estimates of -$0.56.
Analysts are recommending an EPS of between -$1.61 and -$3.24 for the fiscal current year, implying an average EPS of -$2.3. EPS for the following year is -$1.06, with 5 analysts recommending between -$0.78 and -$1.22.
Revenue Estimates
7 analysts predict $56.63M in revenue for the current quarter. It ranges from a high estimate of $59.6M to a low estimate of $53.47M. As of the current estimate, Revance Therapeutics Inc’s year-ago sales were $49.33M, an estimated increase of 14.80% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $68.21M, an increase of 17.30% over than the figure of $14.80% in the same quarter last year. There is a high estimate of $72.83M for the next quarter, whereas the lowest estimate is $64M.
A total of 10 analysts have provided revenue estimates for RVNC’s current fiscal year. The highest revenue estimate was $288M, while the lowest revenue estimate was $272.88M, resulting in an average revenue estimate of $281.72M. In the same quarter a year ago, actual revenue was $234.04M, up 20.40% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $382.52M in the next fiscal year. The high estimate is $406.96M and the low estimate is $341M. The average revenue growth estimate for next year is up 35.80% from the average revenue estimate for this year.
